The stock option award to Dr. Jorgensen provides for the purchase of an aggregate of 200,000 shares of Voyager's common stock, and the restricted stock unit award to Dr. Jorgensen will represent 80,000 shares of Voyager's common stock. The stock option has a ten-year term and an exercise price of $7.79 per share, which is equal to the closing price of Voyager's common stock on July 8, 2024, the effective date of grant. The stock option vests over four years, with 25% of the shares underlying the stock optio ...

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q1 2024 Earnings Conference Call May 13, 2024 4:30 PM ET Company Participants Trista Morrison - Chief Corporate Affairs Officer Alfred Sandrock - CEO Todd Carter - Chief Scientific Officer Toby Ferguson - Chief Medical Officer Robin Swartz - COO and Principal Financial Officer Conference Call Participants Mehdi Goudarzi - Truist Securities Jack Allen - Baird Patrick Trucchio - H.C. Wainwright & Co. Philip Nadeau - TD Cowen Ry Forseth - Guggenheim Securities David Hoa ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION (I.R.S. Employer Identification No.) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission file number: 001-37625 Voyager Therapeutics, Inc. (Exact name of Registrant as specified in its charter) Delaware 46-30031 ...

EXHIBIT 99.1 Voyager Therapeutics Reports First Quarter 2024 Financial and Operating Results – Company announces clearance of IND application with FDA for anti-tau antibody VY-TAU01 for the treatment of Alzheimer's disease; expect to begin single ascending dose trial in the coming weeks – – Development candidates selected for Neurocrine-partnered GBA1 and Friedreich's Ataxia gene therapy programs; potential for three gene therapies, including SOD1- ALS, to enter the clinic in 2025 – – Appointed neurology cl ...

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q4 2023 Results Earnings Conference Call February 28, 2024 4:30 PM ET Company Participants Peter Pfreundschuh - Chief Financial Officer Alfred Sandrock - President and Chief Executive Officer Todd Carter - Chief Scientific Officer Conference Call Participants Jack Allen - Robert W. Baird Sam Beck - Citigroup Jay Olson - Oppenheimer & Co. Ry Forseth - Guggenheim Securities Phil Nadeau - TD Cowen Mehdi Goudarzi - Truist Securities Sumant Kulkarni - Canaccord Genuity In ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37625 Voyager Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 46-3003182 (State o ...

– Company had approximately $431 million in pro-forma cash as of December 31, 2023, adjusted for $100 million consideration from Novartis agreements and $100 million public offering – – Strong cash position and anticipated milestones/reimbursements provide runway into 2027, potentially enabling the generation of clinical data from multiple programs – EXHIBIT 99.1 Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results Key Milestones Achieved in Q4 2023 and Subsequent P ...

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q3 2023 Results Conference Call November 6, 2023 4:30 PM ET Company Participants Pete Pfreundschuh - CFO Dr. Al Sandrock - CEO Dr. Todd Carter - Chief Scientific Officer Conference Call Participants Joon Lee - Truist Securities Jack Allen - Baird Jay Olson - Oppenheimer Laura Chico - Wedbush Yanan Zhu - Wells Fargo Sumant Kulkarni - Canaccord Divya Rao - TD Cowen Operator Good afternoon, and welcome to the Voyager Therapeutics Third Quarter 2023 Conference Call. All ...

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission file number: 001-37625 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 Voyager Therapeutics, Inc. (Exact name of Registrant as specified in its charter) (State or other j ...

Start Time: 08:30 January 1, 0000 9:08 AM ET Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q2 2023 Earnings Conference Call August 03, 2023, 08:30 AM ET Company Participants Al Sandrock - President and CEO Pete Pfreundschuh - CFO Todd Carter - Chief Scientific Officer Conference Call Participants Joon Lee - Truist Securities Ingrid Ibarra - Wedbush Jack Allen - Baird Philip Nadeau - TD Cowen Matthew Hershenhorn - Oppenheimer Ross Fladeland - Canaccord Genuity Operator Good morning and welcome to Voyager Therapeu ...